1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Syngen Biotech Co., Ltd.

Syngen Biotech Co., Ltd.

TTPEX:8279
79.30
TWD
-0.30
(-0.38%)
8.42EPS
10.54P/E
2.41BMarket Cap
Nov 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
14.32
29.03
32.24
35.64
40.54
46.77
54.01
48.39
54.29
71.24
67.79
74.3
78.83
77.34
Basic EPS, GAAP
0.76
1.82
3.35
4.18
6.31
5.8
7.86
7.95
8.77
11.85
10.14
8.86
10.02
8.43
Free Cash Flow per Basic Share
-0.7
-1.51
1.56
0.33
-5.63
-1.17
6.18
-1.94
10.14
-11.34
11.86
10.47
8.97
0.92
Dividend per Share
- -
- -
- -
0.43
0.89
0.91
2.4
3
3.5
4
5
5
5
- -
Book Value per Share
13.03
14.91
19.27
27.04
32.41
37.04
55.03
60
65.36
73.49
78.65
82.51
87.57
86.39
Tangible Book Value per Share
10.26
12.29
17.16
25.61
30.95
35.67
53.93
58.99
64.5
72.64
77.76
81.49
86.17
85.04
Basic Weighted Avg Shares
19
19
20
22
24
23
24
27
27
27
27
27
27
27
Sales/Revenue/Turnover
275
556
644
769
956
1,080
1,297
1,311
1,471
1,931
1,837
2,014
2,136
2,097
Operating Margin (%)
-1.11
7.22
12.84
15.05
18.05
15.92
18.47
19.63
19.15
19.69
16.02
15.41
15.16
13.36
Depreciation Expense
17
22
24
32
39
48
64
77
81
87
99
115
121
117
Net Income, GAAP
15
35
67
90
149
134
189
216
238
321
275
240
272
229
Effective Tax Rate (%)
- -
20.21
21.59
20.89
19.51
23.94
21.43
18.16
19.53
18.96
17.67
19.83
18.89
19.16
Profit Margin (%)
5.33
6.26
10.39
11.72
15.55
12.4
14.55
16.44
16.16
16.64
14.96
11.93
12.71
10.9
Working Capital
72
120
118
162
250
313
781
705
599
393
548
635
622
603
LT Debt
27
81
213
17
87
82
142
186
222
356
386
324
151
146
Total Equity
251
287
401
637
764
873
1,491
1,626
1,771
1,992
2,132
2,236
2,373
2,341
Return on Invested Capital (%)
- -
7.51
11.03
13.02
16.1
11.62
12.95
11.27
10.9
11.67
8.7
8.54
9.58
8.5
Return on Capital (%)
- -
8.55
11.77
13.22
17.82
12.77
13.28
11.76
11.81
13.29
10.09
8.85
10.1
8.83
Return on Common Equity (%)
5.99
12.94
19.46
17.37
21.21
16.37
15.97
13.83
14
17.07
13.33
11
11.78
10.15

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
165
16
128
LT Borrowings
5
- -
- -
LT Finance Leases
146
150
146
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
27
27
27
Market Capitalization
3,144
2,873
2,407

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,141
1,175
1,272
Cash, Cash Equivalents & STI
275
320
205
Accounts Receivable, Net
296
370
369
Inventories
362
428
434
Total Current Liabilities
520
638
669
Payables & Accruals
- -
- -
- -
ST Debt
165
16
128
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.22%
7.88%
6.13%
Free Cash Flow
-394.97%
-213.07%
-14.32%
Net Income, GAAP
17.61%
6.29%
13.07%
Sales/Revenue/Turnover
13.21%
10.85%
6.1%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
468
516
556
475
2,014
2025
486
608
- -
480
2,136
2026
417
593
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.2
1.83
2.67
2.16
8.86
2025
2.26
3.23
- -
1.4
10.02
2026
1.23
2.57
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
5
2025
- -
- -
- -
- -
5
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Wei Jen Chen
Full Time Employees
554
Sector
Health technology
Industry
Biotechnology
Address
Building A Tainan TQ Taiwan 73055
IPO Date
Nov 14, 2014
Website
syngen.com.tw
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Syngen Biotech Co., Ltd. is a Taiwan-based biotechnology company primarily engaged in the development, manufacturing, and sale of biopharmaceutical products and research reagents. The company's core products include recombinant proteins, antibodies, cell culture media, molecular biology reagents, and diagnostic kits. It serves the pharmaceutical, biotechnology, academic research, and clinical diagnostic markets with a portfolio covering life science research tools and biopharmaceutical components. Syngen operates mainly in Taiwan and extends its services internationally. Founded in 1998 and headquartered in Taipei, Syngen Biotech leverages advanced biotechnology processes to provide high-quality, reliable products essential for drug development, disease research, and clinical diagnostics. The company's offerings include recombinant protein products for research and therapeutic purposes; monoclonal and polyclonal antibodies; enzyme-linked immunosorbent assay (ELISA) kits; molecular biology reagents; and custom biotechnology services tailored to client specifications. In recent years, Syngen Biotech has expanded its operations through strategic partnerships and product line enhancements, reflecting its commitment to growth and innovation. Notably, in the past 1-2 years, Syngen has launched new recombinant protein products and expanded its service capabilities to support biopharma clients in the Asia-Pacific region, reinforcing its position in the competitive biotech industry. The company continues to explore alliances to broaden its geographic reach and product offerings, aiming to address emerging needs in the biotech and pharmaceutical sectors. Syngen Biotech is positioned within the biotechnology and life sciences industry, targeting research institutions, pharmaceutical companies, clinical laboratories, and biotech firms. Its operations are supported by a network of subsidiaries and collaborators that enhance its service delivery and innovation capacity. The company’s sustained focus on quality and scientific excellence underpins its market presence and ongoing business expansion.